Bio-Rad Laboratories, Inc. (BIO) Bundle
A Brief History of Bio-Rad Laboratories, Inc. (BIO)
Company Overview
Bio-Rad Laboratories, Inc. (NYSE: BIO) is headquartered in Hercules, California. Founded in 1952 by David Schwartz and Alice Schwartz.
Financial Performance
| Fiscal Year | Revenue | Net Income | Employees |
|---|---|---|---|
| 2022 | $2.77 billion | $175.1 million | 9,700 |
| 2023 | $2.64 billion | $140.3 million | 9,500 |
Business Segments
- Life Science Research
- Clinical Diagnostics
- Diabetes Monitoring
Global Presence
Operates in over 40 countries with manufacturing facilities in the United States, United Kingdom, France, and China.
Stock Performance
| Stock Symbol | Current Price (2024) | Market Capitalization | 52-Week Range |
|---|---|---|---|
| BIO | $368.45 | $10.9 billion | $290.14 - $456.23 |
Research and Development
Annual R&D investment of $347 million in 2022, representing 12.5% of total revenue.
Key Products
- Droplet Digital PCR Technology
- QX200 Droplet Digital PCR System
- Clinical Diagnostic Instruments
A Who Owns Bio-Rad Laboratories, Inc. (BIO)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 3,185,842 | 11.5% |
| BlackRock Inc. | 2,894,752 | 10.4% |
| Dimensional Fund Advisors LP | 1,782,341 | 6.4% |
| State Street Corporation | 1,456,789 | 5.2% |
Insider Ownership
As of the latest SEC filing, Norman Schwartz (Executive Chairman) owns 0.5% of the company's shares.
Ownership Structure
- Public Float: 88.6%
- Insider Ownership: 1.2%
- Institutional Ownership: 76.3%
Top Institutional Investors
| Investor | Total Value | Change in Position |
|---|---|---|
| Vanguard Total Stock Market Index Fund | $218,456,000 | +2.3% |
| iShares Core S&P Small-Cap ETF | $156,789,000 | +1.7% |
Ownership Distribution
Public shareholders own 98.8% of Bio-Rad Laboratories, Inc. common stock.
Bio-Rad Laboratories, Inc. (BIO) Mission Statement
Corporate Mission Overview
Bio-Rad Laboratories, Inc. focuses on developing, manufacturing, and marketing innovative life science research and clinical diagnostic products.
| Financial Metric | 2023 Value |
|---|---|
| Annual Revenue | $2.87 billion |
| Net Income | $239.4 million |
| Research & Development Spending | $336.2 million |
Strategic Focus Areas
- Life Science Research Solutions
- Clinical Diagnostics
- Pharmaceutical Development Support
Product Portfolio Segments
| Product Category | Market Share |
|---|---|
| Protein Purification | 15.7% |
| PCR Technologies | 12.3% |
| Immunoassay Diagnostics | 9.6% |
Global Operational Metrics
- Employees: 9,200
- Countries Served: 35
- Manufacturing Facilities: 12
Research and Innovation Investment
Bio-Rad allocates 11.7% of annual revenue to research and development initiatives.
Market Positioning
Ranked as a top-tier life sciences technology provider with consistent global market presence.
How Bio-Rad Laboratories, Inc. (BIO) Works
Company Overview
Bio-Rad Laboratories, Inc. is a global life science research and clinical diagnostic products manufacturer. Headquartered in Hercules, California, the company operates with 7,700 employees as of 2023.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Annual Revenue | $2.99 billion |
| Net Income | $237.4 million |
| Gross Margin | 54.3% |
Business Segments
- Life Science Research
- Clinical Diagnostics
- Specialty Diagnostics
Product Categories
Life Science Research Products include:
- Protein purification systems
- Electrophoresis equipment
- Antibodies and reagents
- Droplet digital PCR technologies
Global Market Presence
Bio-Rad operates in 25 countries with direct sales and distribution networks across multiple continents.
Research and Development
R&D investment in 2023: $356.2 million, representing 11.9% of total revenue.
Stock Performance
| Stock Metric | 2023 Value |
|---|---|
| Stock Price (Average) | $579.45 |
| Market Capitalization | $17.3 billion |
How Bio-Rad Laboratories, Inc. (BIO) Makes Money
Revenue Streams
Bio-Rad Laboratories, Inc. generates revenue through two primary business segments:
| Segment | 2022 Revenue | Primary Products/Services |
|---|---|---|
| Life Science | $1.08 billion | Research reagents, clinical diagnostic instruments |
| Clinical Diagnostics | $1.01 billion | Diabetes monitoring, blood typing, infectious disease testing |
Product Portfolio
- Protein purification systems
- Electrophoresis equipment
- Polymerase chain reaction (PCR) technologies
- Diabetes monitoring solutions
- Immunoassay analyzers
Market Segments
Bio-Rad serves multiple markets:
- Academic research institutions
- Pharmaceutical companies
- Biotechnology firms
- Clinical laboratories
- Hospitals
Financial Performance
| Financial Metric | 2022 Value |
|---|---|
| Total Revenue | $2.89 billion |
| Gross Profit Margin | 55.2% |
| Net Income | $237.4 million |
Geographic Revenue Distribution
| Region | Percentage of Revenue |
|---|---|
| United States | 57% |
| Europe | 24% |
| Other International Markets | 19% |
Bio-Rad Laboratories, Inc. (BIO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.